SPI
18.551,09
PKT
+155,85
PKT
+0,85
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu SPI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 12.04.12 | Swatch (I) buy | Sarasin Research | |
| 11.04.12 | Givaudan sell | Deutsche Bank AG | |
| 11.04.12 | Novartis buy | UBS AG | |
| 11.04.12 | Givaudan neutral | Sarasin Research | |
| 11.04.12 | Roche neutral | Nomura | |
| 10.04.12 | Clariant hold | Deutsche Bank AG | |
| 10.04.12 | Peach Property Group buy | SRC Research GmbH | |
| 10.04.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 10.04.12 | UBS underperform | Cheuvreux SA | |
| 10.04.12 | Sonova kaufen | Die Actien-Börse | |
| 05.04.12 | Holcim sell | Citigroup Corp. | |
| 05.04.12 | Roche outperform | Credit Suisse Group | |
| 05.04.12 | Nestlé overweight | HSBC | |
| 04.04.12 | TX Group buy | Sarasin Research | |
| 04.04.12 | Barry Callebaut sell | Société Générale Group S.A. (SG) | |
| 04.04.12 | UBS neutral | Credit Suisse Group | |
| 03.04.12 | Nestlé kaufen | Norddeutsche Landesbank (Nord/LB) | |
| 03.04.12 | Givaudan neutral | Nomura | |
| 03.04.12 | Clariant neutral | Nomura | |
| 03.04.12 | Zurich Insurance neutral | Sarasin Research | |
| 03.04.12 | Lonza neutral | Sarasin Research | |
| 03.04.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 03.04.12 | Julius Bär equal-weight | Morgan Stanley | |
| 03.04.12 | UBS buy | Goldman Sachs Group Inc. | |
| 02.04.12 | UBS neutral | Nomura | |
| 02.04.12 | UBS buy | Nomura | |
| 02.04.12 | Novartis buy | Sarasin Research | |
| 02.04.12 | Barry Callebaut neutral | Sarasin Research | |
| 30.03.12 | UBS underperform | Exane-BNP Paribas SA | |
| 30.03.12 | UBS underperform | Exane-BNP Paribas SA | |
| 30.03.12 | Roche neutral | WestLB AG | |
| 30.03.12 | Orascom Development neutral | Sarasin Research | |
| 30.03.12 | Holcim neutral | HSBC | |
| 30.03.12 | Holcim outperform | Exane-BNP Paribas SA | |
| 30.03.12 | Roche outperform | Exane-BNP Paribas SA | |
| 30.03.12 | Barry Callebaut sell | Société Générale Group S.A. (SG) | |
| 29.03.12 | Roche overweight | J.P. Morgan Cazenove | |
| 29.03.12 | Huber + Suhner sell | UBS AG | |
| 29.03.12 | Zurich Insurance neutral | Sarasin Research | |
| 29.03.12 | Swisscom neutral | Sarasin Research |